Clinical-stage biotechnology company developing next-generation cancer immunotherapies for immune-excluded tumors
Clinical-stage biotechnology company developing next-generation cancer immunotherapies for immune-excluded tumors. Its lead program, IMGS-001, is a dual-specific cytotoxic antibody targeting PD-L1 and PD-L2, designed to block PD-1 pathway signaling and eliminate immunosuppressive cells so T cells can enter and attack tumors. IMGS-101 (evofosfamide) is a hypoxia-reversal agent intended to reoxygenate the tumor microenvironment and improve immune-cell access.